Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Up 33.8% in February

Posted by Caroline Horne on Mar 16th, 2025

Portage Biotech Inc. (NASDAQ:PRTG – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 17,400 shares, a growth of 33.8% from the February 13th total of 13,000 shares. Based on an average daily volume of 650,300 shares, the short-interest ratio is currently 0.0 days. Currently, 10.6% of the shares of the stock are sold short.

Institutional Investors Weigh In On Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC acquired a new stake in Portage Biotech Inc. (NASDAQ:PRTG – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned approximately 1.04% of Portage Biotech at the end of the most recent quarter. 13.36% of the stock is owned by institutional investors and hedge funds.

Portage Biotech Stock Performance

Shares of NASDAQ PRTG traded up $0.17 during mid-day trading on Friday, hitting $4.21. 21,785 shares of the stock were exchanged, compared to its average volume of 646,667. Portage Biotech has a twelve month low of $2.10 and a twelve month high of $23.01. The stock’s fifty day simple moving average is $4.44 and its two-hundred day simple moving average is $4.97. The company has a market cap of $4.42 million, a P/E ratio of -0.10 and a beta of 1.29.

About Portage Biotech

(Get Free Report)

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.